Danny Sullivan

Glasgow

Contributing Editor at Longevity Technology

Contributing Editor at @LongevityTech. Writer, marketer, PR'er, traveller, reader, runner, technolover and lots of other ers...

Featured in: Favicon

longevity.technology Favicon

flipboard.com

Articles

Juvenescence acquires Ro5 to bolster AI drug discovery

3 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech powerhouse Juvenescence has expanded its AI-driven drug discovery capabilities through the acquisition of Ro5, a company specializing in AI and machine learning platforms for pharmaceutical research. The strategic move aims to accelerate the development of Juvenescence’s pipeline of therapeutics targeting age-related diseases, also strengthens its ongoing partnership with Abu Dhabi healthcare giant M42.
Risky business: Polygenic risk scores and the path to prevention

3 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Last month, British healthtech firm Genomics Ltd announced a collaboration with Danish pharmaceutical giant Novo Nordisk to identify individuals who are genetically predisposed to obesity by combining polygenic risk scores (PRS) with clinical factors. Polygenic risk scores estimate a person’s inherited risk for complex traits or diseases by aggregating the influence of thousands – or even millions – of common genetic variants, each with a small effect.
Insilico’s IPF drug demonstrated ‘clinically meaningful’ benefits

4 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity focused AI-powered drug developer Insilico Medicine has published the results of its Phase 2a idiopathic pulmonary fibrosis (IPF) clinical trial results in Nature Medicine. The trial studied the efficacy of Rentosertib, a novel TNIK inhibitor developed using the company’s generative AI platform, in the treatment of patients with IPF.
Magnitude Biosciences lands funding to accelerate longevity drug development

5 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp UK-based contract research organization Magnitude Biosciences, has secured more than £700,000 in combined investment and grant funding to advance its high-throughput drug discovery platform for in vivo testing using the transparent nematode (worm) model C elegans.
Prevention-focused unicorn Omada Health plots IPO

6 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Tech-enabled preventive healthcare company Omada Health aims to raise $158 million in an initial public offering that reportedly values the company at around $1.1 billion. Since 2012, Omada has evolved from a virtual diabetes and weight management provider into a comprehensive prevention platform, which is primarily focused on driving “behavior change” to improve the health of its members.
BioAge plots clinical trial of NLRP3 inhibitor this year

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech BioAge Labs has announced the completion of investigational new drug (IND)-enabling studies for BGE-102, the company’s novel small-molecule NLRP3 inhibitor, as it advances toward clinical development. BGE-102 is designed as an orally available, brain-penetrant compound with high potency, and it is being developed initially for the treatment of obesity.
Vivodyne lands $40m to replace animal testing in drug development

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp US biotech Vivodyne has secured $40 million in Series A funding led by Khosla Ventures for its mission to eliminate the need for animal testing drug development. The company leverages robotics and AI to grow and analyze thousands of fully functional human tissues, directly addressing the biological mismatch that underpins the staggering 95% failure rate in human clinical trials following successful animal tests.
Tally Health teams up with Pvolve and Cenegenics

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Consumer longevity biotech Tally Health has announced two new partnerships focused on advancing personalized approaches to managing aging. The strategic collaborations – with performance health company Cenegenics and functional fitness brand Pvolve – seek to integrate Tally’s epigenetic science with lifestyle-based wellness strategies to drive healthspan improvements.
Neuralink raises $600m to advance brain-computer interface tech

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Neuralink, the brain-computer interface (BCI) company founded by Elon Musk, has reportedly closed a huge round of funding, raising a staggering $600 million at a valuation of around $9 billion.
Human trial finds therapeutic plasma exchange reduces biological age

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp A clinical study published this week in Aging Cell suggests that therapeutic plasma exchange (TPE), can significantly reduce biological age, particularly when combined with intravenous immunoglobulin (IVIG). Conducted by TPE provider Circulate Health in collaboration with the Buck Institute for Research on Aging, the single-blind human trial is believed to be the first to assess the rejuvenative potential of TPE using comprehensive molecular profiling.